Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

被引：1087

作者：

Topalian, Suzanne L. ^{[1
,2
]}

Drake, Charles G. ^{[2
,3
,4
]}

Pardoll, Drew M. ^{[2
,3
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21287 USA

[2] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA

[3] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA

[4] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2012年 / 24卷 / 02期

关键词：

CHRONIC VIRAL-INFECTION; CD8(+) T-CELLS; B7; FAMILY; IN-VIVO; PHASE-I; PD-1; B7-H1; EXPRESSION; EFFECTOR; RECEPTOR;

D O I：

10.1016/j.coi.2011.12.009

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Genetic alterations and epigenetic dysregulation in cancer cells create a vast array of neoepitooes potentially recognizable by the immune system. Immune checkpoint blockade has the capacity to enhance and sustain endogenous immunity against non-mutated tumor-associated antigens as well as uniquely mutant antigens, establishing durable tumor control. Recent evidence from preclinical models highlights the pivotal role of the Programmed Death-1 (PD-1) T cell co-receptor and its ligands, B7-H1/PD-L1 and B7-DC/PD-L2, in maintaining an immunosuppressive tumor microenvironment. Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy.

引用

收藏

页码：207 / 212

页数：6

相关论文

共 42 条

[1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[2] The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells [J].

Amarnath, Shoba ;

Mangus, Courtney W. ;

Wang, James C. M. ;

Wei, Fang ;

He, Alice ;

Kapoor, Veena ;

Foley, Jason E. ;

Massey, Paul R. ;

Felizardo, Tania C. ;

Riley, James L. ;

Levine, Bruce L. ;

June, Carl H. ;

Medin, Jeffrey A. ;

Fowler, Daniel H. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (111)

[3] B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells [J].

Azuma, Takeshi ;

Yao, Sheng ;

Zhu, Gefeng ;

Flies, Andrew S. ;

Flies, Sarah J. ;

Chen, Lieping .

BLOOD, 2008, 111 (07) :3635-3643

[4] Restoring function in exhausted CD8 T cells during chronic viral infection [J].

Barber, DL ;

Wherry, EJ ;

Masopust, D ;

Zhu, BG ;

Allison, JP ;

Sharpe, AH ;

Freeman, GJ ;

Ahmed, R .

NATURE, 2006, 439 (7077) :682-687

[5] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].

Benson, Don M., Jr. ;

Bakan, Courtney E. ;

Mishra, Anjali ;

Hofmeister, Craig C. ;

Efebera, Yvonne ;

Becknell, Brian ;

Baiocchi, Robert A. ;

Zhang, Jianying ;

Yu, Jianhua ;

Smith, Megan K. ;

Greenfield, Carli N. ;

Porcu, Pierluigi ;

Devine, Steven M. ;

Rotem-Yehudar, Rinat ;

Lozanski, Gerard ;

Byrd, John C. ;

Caligiuri, Michael A. .

BLOOD, 2010, 116 (13) :2286-2294

[6] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

[7] Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].

Blackburn, Shawn D. ;

Shin, Haina ;

Haining, W. Nicholas ;

Zou, Tao ;

Workman, Creg J. ;

Polley, Antonio ;

Betts, Michael R. ;

Freeman, Gordon J. ;

Vignali, Dario A. A. ;

Wherry, E. John .

NATURE IMMUNOLOGY, 2009, 10 (01) :29-37

[8] PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].

Blank, C ;

Brown, I ;

Peterson, AC ;

Spiotto, M ;

Iwai, Y ;

Honjo, T ;

Gajewski, TF .

CANCER RESEARCH, 2004, 64 (03) :1140-1145

[9] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[10] Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses [J].

Butte, Manish J. ;

Keir, Mary E. ;

Phamduy, Theresa B. ;

Sharpe, Arlene H. ;

Freeman, Gordon J. .

IMMUNITY, 2007, 27 (01) :111-122

← 1 2 3 4 5 →